Cognition Therapeutics (CGTX) Change in Accured Expenses (2020 - 2026)

Cognition Therapeutics (CGTX) has reported Change in Accured Expenses for 7 consecutive years, with -$7.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 9993.33% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$4.0 million (down 284.83% YoY), while the FY2025 annual figure was $3.5 million, up 89.32% from the prior year.
• Change in Accured Expenses declined to -$7.6 million in Q1 2026 per CGTX's latest filing, from $8.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $8.4 million in Q4 2025 and bottomed at -$7.6 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$30294.1 across 5 years, with a median of -$75000.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 611.3% — and 2026, when it slumped 9993.33%.
• Cognition Therapeutics' Change in Accured Expenses stood at -$5.2 million in 2022, then soared by 111.53% to $603000.0 in 2023, then slumped by 397.84% to -$1.8 million in 2024, then surged by 568.49% to $8.4 million in 2025, then sank by 189.97% to -$7.6 million in 2026.
• Business Quant data shows CGTX's Change in Accured Expenses at -$7.6 million in Q1 2026, $8.4 million in Q4 2025, and -$5.4 million in Q3 2025.